Rallybio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Rallybio şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-12.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-12.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Jul 07

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

Mar 16

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RLYB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RLYB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Rallybio Piyasaya Karşı Temettü Getirisi

RLYB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RLYB)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (RLYB) (3 yıla kadar)	n/a

Önemli Temettü: RLYB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RLYB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RLYB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RLYB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Rallybio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Rallybio Corporation Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Consensus revenue estimates increase by 33%

Rallybio Corporation Announces Initiation of Phase 2 Clinical Trial of RLYB212

Consensus EPS estimates upgraded to US$1.34 loss

New minor risk - Profitability

Rallybio Announces Publication of RLYB212 Phase 1 Proof-Of-Concept Study Results in Thrombosis and Haemostasis

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Price target decreased by 19% to US$10.50

Rallybio Corporation(NasdaqGS:RLYB) dropped from Russell 3000 Index

Rallybio Corporation Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Rlybocytopenia

Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.38

Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116

Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212

New major risk - Share price stability

New minor risk - Market cap size

Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Price target decreased by 7.3% to US$16.83

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Reports Data from the Phase 1b Proof-Of-Concept Study of RLYB212

Price target decreased by 9.9% to US$18.17

Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Price target decreased by 7.2% to US$22.50

Rallybio Corporation Announces Chief Financial Officer Changes

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1A-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT

Price target decreased to US$28.00

High number of new directors

Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Price target increased to US$30.67

Rallybio Corporation Expects to Discuss the Preliminary Platelet Elimination Data by the End of the Third Quarter of 2022

Rallybio Corporation Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Corporation Announces Retirement of Jeffrey Fryer as Chief Financial Officer

High number of new directors

Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

High number of new directors

Rallybio Corporation, Annual General Meeting, May 24, 2022

High number of new directors

Rallybio Corporation Announces Board Changes

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

CEO & Chairman recently bought US$103k worth of stock

High number of new directors

Rallybio Corporation Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin